14 Dec 2017

We are excited to join hands with five experienced early phase new drug development institutions in the formation of the Asian Oncology Early Phase 1 Consortium. Following the signing of a Memorandum of Understanding (MOU) earlier between The Chinese University of Hong...

15 Jun 2017

The large-scale international study on “Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer” shows Alectinib, a second-generation ALK inhibitor, to be twice as effective and efficient as Crizotinib, the current standard treatment for ALK-po...

Please reload

Recent Posts

Please reload